Exicure, Inc.

Exicure, Inc. is a biotechnology company based in Chicago, Illinois, founded in 2011. It specializes in the development of therapies for neurological disorders and hair loss using its proprietary spherical nucleic acid (SNA) technology. The company’s lead program candidate, SCN9A, is currently in preclinical studies for chronic and neuropathic pain.

In addition to its research and development efforts, Exicure, Inc. has entered into multiple collaborations, option and license agreements to expand its drug pipeline. In 2013, the company signed a multi-year collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders. Furthermore, in 2018, Exicure, Inc. entered into a collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington’s disease and Angelman syndrome.

In addition to its collaborations, Exicure, Inc. has received numerous grants from prominent organizations, such as the National Institutes of Health (NIH), the National Science Foundation (NSF), and the US Department of Defense. It has also been the recipient of several awards, including the 2017 Fierce Innovation Awards: Life Sciences Edition and the 2018 Fierce 15.

Exicure, Inc. is led by a team of experienced industry veterans and scientists. The company’s core competencies are in the discovery and clinical development of nucleic acid based therapies and it is committed to developing therapies to treat diseases with high unmet needs. To this end, it is focused on discovering, developing, and ultimately commercializing novel treatments for neurological disorders, gene regulation related diseases, and hair loss.